Back
Embecta faces securities class action after 57.8% stock plunge over insulin pen needle claims

Embecta faces securities class action after 57.8% stock plunge over insulin pen needle claims

A New Jersey federal suit and a parallel Hagens Berman investigation allege the medical device company overstated the stability of its pen needle business before weak results, a dividend cut and a share collapse.

Fact Check
Every element of the claim is corroborated. The Bleichmar Fonti & Auld case page and press releases confirm a securities class action filed in the U.S. District Court for the District of New Jersey (Apitz-Grossman v. Embecta Corp., No. 26-cv-07217) alleging Embecta overstated the resilience of its insulin pen needle business while concealing competition and market softness. The 57.8% single-day stock plunge (from $9.25 on May 4 to $3.90 on May 5, 2026), the weak Q2 FY2026 results, and the dividend cut from $0.15 to $0.01 per share are confirmed both in the legal filings and independently by Embecta's own earnings release (via investors.embecta.com), Seeking Alpha, Yahoo Finance, and Hagens Berman. No conflicting evidence was found.
Summary

Embecta Corp. is facing a securities class action in the U.S. District Court for the District of New Jersey and a parallel Hagens Berman investigation over claims that the company and certain senior executives misled investors from Nov. 25, 2025 to May 4, 2026 about the stability of its insulin pen needle business despite competitive share loss and weaker retail demand. The complaint, captioned Apitz-Grossman v. Embecta Corp., et al., asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alleging Embecta described the portfolio as "stable," "resilient," and "incredibly resolute" while reaffirming guidance. Plaintiffs say the gap between those assurances and underlying conditions surfaced on May 5, 2026, when Embecta reported second-quarter 2026 results below guidance, cited share loss in the pen needle category largely tied to a single customer and broader retail-channel softness, cut full-year adjusted EPS guidance by about 43% at the midpoint, reduced its quarterly dividend to $0.01 from $0.15 and saw the stock fall 57.8% to $3.90 from $9.25. Investors have until Aug. 17, 2026 to seek appointment as lead plaintiff.

Terms & Concepts
  • class action: A lawsuit brought by one or more plaintiffs on behalf of a larger group with similar claims.
  • Sections 10(b) and 20(a): U.S. securities law provisions commonly cited in fraud cases, covering deceptive conduct and liability for controlling persons.
  • lead plaintiff: The investor appointed by the court to act on behalf of the broader shareholder class.